Cardiotoxicity is a common cause of attrition in preclinical and clinical drug development. Current in vitro approaches have two main limitations, they either are limited to low throughput methods not amendable to drug discovery or lack the physiological responses to allow an integrated risk assessment. A human 3D cardiac microtissue containing humaninduced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), cardiac endothelial cells and cardiac fibroblast were used to assess their suitability to detect drug induced changes in cardiomyocyte contraction. These cardiac microtissues, have a uniform size, spontaneously beat, lack a hypoxic core, and contain key markers of each cell type. Application of field stimulation and measurement of cardiac contraction confirm cardiac microtissues to be a suitable model to investigate drug-induced changes in cardiomyocyte contractility. Using a bespoke image acquisition work flow and optical flow analysis method to test 29 inotroptic and 13 non-inotroptic compounds in vivo. We report that cardiac microtissues provide a high-throughput experimental model that is both able to detect changes in cardiac contraction with a sensitivity and specificity of 80 and 91%, respectively, and provide insight into the direction of the inotropic response. Allowing improved in vitro cardiac contractility risk assessment. Moreover, our data provide evidence of the detection of this liability at therapeutically relevant concentrations with a throughput amenable to drug discovery.
Non-clinical and clinical safety remains a key cause of attrition throughout drug discovery and development (Cook et al., 2014; Waring et al. 2015; Weir et al., 2015) . Analysis of the target organs responsible reveals, effects on the cardiovascular system to be a major contributing factor (Cook et al., 2014; Laverty et al, 2011) . Consequently, developing preclinical approaches both in vitro and in vivo to identify and where feasible eliminate cardiovascular-related safety, is a key priority for the pharmaceutical industry (Lu et al., 2015; Morton et al., 2014) .
Drug-induced cardiotoxicity can affect all components and functions of the cardiovascular system, either directly or indirectly and can be functional (acute alteration of the mechanical function of the myocardium) and or structural (morphological damage to cardiomyocytes and/or loss of viability, changes in cell signaling and intracellular organelles) in nature, as previously defined by Laverty et al. (2011) . Current drug discovery in vitro strategies for the detection of functional cardiotoxicity are predominately focused on drug-induced ECG abnormalities as detected by high-throughput screening of ion channels implicated in functional cardiotoxicity (eg, hERG) (Navarrete et al., 2013; Pollard et al., 2008 Pollard et al., , 2010 Xi et al., 2011) . However, cardiovascular functional abnormalities can also arise through changes in hemodynamic properties, in particularly changes in heart rate, blood pressure and cardiac contractility. Clinically, changes in cardiac contractility are characterized by changes in the left ventricular ejection fraction (LVEF) . Both decreases and increases in cardiac contractility can be detrimental, depending on the susceptible patient population, resulting in the development of heart failure and increased mortality (Wallis et al., 2015) . For example, a positive inotropic effect causes an increase in myocardial oxygen demand, which in patients with normal cardiac function maybe without consequence; however, in patients with coronary artery disease can led to myocardial hypoxia (Packer et al., 1991; Wallis et al., 2015) . Conversely, a negative inotropic effect can induce heart failure (Ahmad et al., 2001 ). These differences in the risk associated with negative and positive inotropic compounds highlight the importance of an in vitro model that is able to discriminate between them to influence the risk assessment of a novel compound.
Drug discovery or development is often halted or delayed due to changes in cardiac contractility. A recent analysis suggests as many as 68% of candidate drugs, when tested in vivo, demonstrate a significant change in cardiac contractility (Skinner et al., 2012) . This results in drug attrition, increased costs, altered clinical use, label warnings and drug withdrawal from the market (Force et al., 2007; Mellor et al., 2011; Murphy and Dargie, 2007; Pointon et al., 2015; Slordal and Spigset, 2006) .
Preclinical models to assess novel compounds for a cardiac contractility risk include both in vivo and in vitro approaches. In vitro assessments have traditionally ranged from single organ/ cell assays (low throughput), eg, the isolated whole heart model utilizing pre-clinical species (Guo et al., 2009) , isolated ventricular cardiomyocytes from preclinical species (Harmer et al., 2012) to 24-well plate assays (medium throughput) eg, "heart on a chip" technology (Grosberg et al., 2011 (Grosberg et al., , 2012 . These approaches allow detailed assessment and quantification of contraction and relaxation kinetics; however, they are limited by throughput, thus reducing their influence over chemical design and the occurrence of effects on cardiac contractility.
Over recent years, the use of stem cell-derived cardiomyocytes has led to the development of a number of high-throughput screening approaches to detect changes in cardiac contractility Scott et al., 2014) . These approaches are able to generate thousands of data points a day, generating data that can be used to influence chemical design of novel compounds and consequently reduce the occurrence of effects on cardiac contractility, which can occur due to a range of cellular mechanisms. Although the predictivity of these approaches is good with regard to a change in activity, they lack an ability to discriminate between positive and negative inotropes. For example several positive inotropes, like negative inotropes, produce a decreased peak count and amplitude using current assay technology . These observations suggest an improved model is required to provide an integrated risk assessment for the occurrence of cardiac contractility. A scaffold-free, human cardiac microtissue has been recently developed containing the 3 major cardiac cell types present within the heart; cardiomyocytes (human embryonic stem cell-derived cardiomyocytes), cardiac fibroblasts and cardiac endothelial cells (Ravenscroft et al., 2016) . These novel 3D microtissues provide an opportunity to improve detection of cardiovascular side effects; however, they are still associated with ethical concerns around the use of human embryonic stem cells.
Here we have developed a 3D cardiac microtissue that overcomes the ethical concerns of using human embryonic stem cell-derived cardiomyocytes, by using human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), cardiac fibroblasts and cardiac endothelial cells. We have profiled a panel (42 compounds) of in vivo clinical and preclinical cardiac contraction modulators, which represent diverse mechanisms of effect, in a novel plate-based imaging work flow, allowing quantification of changes in cardiac contraction at a throughput amenable to drug discovery. We demonstrate that this experimental approach is able to overcome the limitations of monolayer hiPS-CM contractility assays. It is capable of predicting the potential for drug-induced effects on cardiac contractility in terms of risk identification and direction of response during early phases of drug discovery, in the context of clinically relevant concentrations, allowing identification and mitigation of cardiac contractility risks.
MATERIALS AND METHODS
Materials. All reagents were purchased from Sigma-Aldrich (St Louis, Missouri) or synthesized in-house. Cell culture consumables were purchased from VWR (Lutterworth, UK) unless stated otherwise and were of the highest purity/grade available. CellTiter-Glo Luminescent Cell Viability Assay Kit was purchased from Promega (Madison, Wisconsin).
Compound preparation. Compound classification of inotropic effects was gathered using Pharmapendium (https://www.phar mapendium.com) or internal databases for AstraZeneca drug candidates. A compound was classified as an inotrope if a change in LVEF or dP/dt max was reported either clinically or preclinically (dog or non-human primate), respectively. Whereas all compounds without a change in either LVEF or dP/ dt max we classified as non-inotropes. Full details of all compounds tested can be found in Supplementary Table S1 .
Compounds were initially formulated in dimethyl sulfoxide (DMSO) as a 1000Â stock solution (w/v). Insolubility and precipitation were not seen with any compound (assessed by visual inspection). Test compounds were prepared using 6 concentrations in a half log 10 dilution scheme. Stock solutions were subsequently diluted 1000Â in microtissue media (50% iCell cardiomyocytes maintenance media [Cellular Dynamics International] and 50% endothelial basal medium MV2 [PromoCell] ) to give the final test concentrations. The final DMSO concentration was 0.1% (v/v). Compounds were screened in duplicate on 4 separate occasions.
Cell culture. hiPS-CMs (iCell Cardiomyocytes), cardiomyocyte cell culture thawing and maintenance media were purchased from Cellular Dynamics International (cat no. CMM-100-120-005) (Madison, Wisconsin) . Differentiation protocols and cell culture conditions were as detailed in Ma et al.(2011) . Primary human cardiac microvascular endothelial cells (hCMECs) and primary human cardiac fibroblasts (hCFs) were obtained from PromoCell (Heidelberg, Germany). hCMECs were cultured in endothelial basal medium MV2 (PromoCell, C-22221) (supplemented with 5% FCS, EGF (5 ng ml À1 ), bFGF (10 ng ml À1 ), IGF (20 ng ml À1 ), VEGF (0.5 ng ml À1 ), Ascorbic Acid (1 lg ml À1 ), and Hydrocortisone (0.2 mg ml À1 ). hCFs were cultured in fibroblast growth medium 3
(PromoCell, C-23025). Both hCMECs and hCFs were sub-cultured prior to microtissue formation according to supplier's instructions.
Microtissue formation. All primary cells were detached with prewarmed TrypLE (ThermoFisher Scientific cat no. 12605010) for 3 min at 37 C, 5% CO 2 , centrifuged for 2 min at 1200 Â g before re-suspension in endothelial basal medium. Cell suspensions were counted, diluted and stored at 37 C, 5% CO 2 for up to 30 min while hiPS-CM cell suspensions were prepared. iCell cardiomyocytes were thawed and suspended in iCell thawing media as described previously . Cell suspensions were combined to give a concentration of 500 cells per 40 ll comprising 2 parts hiPS-CM and one part hCF/hCMEC in thawing microtissue media (50% iCell thawing media, 50% endothelial basal medium). Suspensions were subsequently seeded into round bottom ultra-low adhesion 384-well plates (Corning Costar, CLS3830). After 48 h, culture media was refreshed with 40 ll 50% iCell CM maintenance media and 50% endothelial basal medium (microtissue maintenance media). All microtissue plates were incubated at 37 C, 5% CO 2 for 14 days with media refreshed every 3-4 days (40 ll media removed and 40 ll fresh media applied).
Confocal imaging. Immunoflourescence was conducted on the microtissues as described previously in Ravenscroft et al. (2016) . Gene expression analysis. Adult left ventricle total RNA (21-year old normal male donor with no reported concomitant disease) was purchased from U.S. Biologic (Memphis, USA). Microtissues were pooled and transferred into a falcon tube, and allowed to pellet by gravity over a period of 5 min and re-suspended in pre-warmed PBS. Microtissues were re-pelleted by gravity over a period of 5 min and lysed in RLT buffer (Qiagen). Total RNA was extracted using an RNeasy Mini Kit (Qiagen). A NanoDrop spectrophotometer (NanoDrop Technologies) was used to quantify RNA samples. RNA samples were diluted to 100 ng and reverse transcribed using the SuperScript III first-strand synthesis supermix (Life Technologies). qRT-PCR was performed using 2 ll of cDNA, TaqMan Gene Expression master mix and the TaqMan Gene Expression probes of interest (Supplementary Table S2 ). Amplification was monitored under standard cycling conditions using a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, California). GAPDH was used as an endogenous control. Relative quantification of gene expression was performed using the DDCt relative quantitation method. The mean Ct value was calculated for each gene and normalized to the endogenous control, fold change relative to adult left ventricle was determined.
Measurement of cell contraction using IonOptix. Microtissues were transferred onto 0.1% (w/v) gelatin-coated 13-mm plastic coverslips (Thermanox) within a 12-well plate and incubated at 37 C, 5% CO 2 for at least 4 h before mounting onto the IonOptix contractility system. Microtissues were continuously perfused with culture media (microtissue maintenance media) at 35.5 6 1 C. When required, microtissues were field stimulated by means of platinum wires within the chamber, with a suprathreshold voltage applied over a range of frequencies. Contraction of microtissues was assessed using a video-based edge detection system (IonOptix, Dublin, Ireland) to continuously measure the movement of a selected point of the microtissue. For each test condition, 10 or more transients were averaged and the transient peak height was determined using IonWizard software (IonOptix, Dublin, Ireland). For concentration-response experiments, 0.1% DMSO (v/v) was first applied, followed by cumulative concentrations of a compound.
Time lapse imaging on ImageXpress. Time lapse images of beating cardiac microtissues were captured using an ImageXpress XL fitted with an environmental chamber (37 C and 5% CO 2 ).
Sequential transmitted light images were captured with a 10 Â Nikon Plan Fluor objective (0.3 NA, 16 mm WD) and a PCO.SDK sCMOS camera with a 4 Â 4 bin, yielding an effective image size of 540 Â 540 pixels at 2.608 mm/pixels. Images were acquired at a frame rate of approximately 35 fps. Untreated cardiac microtissues were imaged for approximately 10 s (400 images acquired) prior to addition of a 5-fold concentration of compound or vehicle control using the pipetting station of the ImageXpress. These images are termed premeasurement. Following a 5-min incubation, a second set of 400 images was acquired. These images are termed postmeasurement. Image acquisition, compound treatment and incubation were controlled in an automated fashion using a bespoke journal for the ImageXpress XL.
Image analysis of ImageXpress data. Each experiment was stored in a specific directory and consisted of 2 sets of 400 uncompressed 16 bits TIF images (540 Â 540 pixels) for respectively the pre-and post-measurements. An automated script was developed in MATLAB (R2015b version 8.6.0.267246. Natick, Massachusetts: The MathWorks Inc., 2010). Each set of 400 images was then analyzed independently in chronological order based on the following framework:
Region of interest localization. The region of interest, empirically defined as a square of 151 Â 151 pixels, was localized within the first frame of the sequence, and used to crop each individual frame of the rest of the experiment's acquisition. To identify the spatial localization of the region of interest, an initial automated global threshold was computed, and increased by a factor of 1.4, using the Otsu's method to minimize the interclass variance of the black and white pixels. Based on this threshold, a binary image was computed and structures connected to the image border rejected to prevent edge effect artefacts. A morphological closing operation using a binary disk radius of 5 as a structuring element was then applied to the image. Finally the region of interest was localized on the centroid of the largest of connected component and stored for visual quality control assessment. This region was then used to crop each individual image and the rest of the analysis preformed within this region only to improve the signal quality.
Deformation quantification. The optical flow was then calculated between 2 consecutive frames, and was based on an implementation of a continuous, rotationally invariant energy functional algorithm (Brox et al., 2004) . The algorithm was restricted to a single scale analysis with a global smoothness variable a ¼ 30 and a weight for derivatives c ¼ 80. The output of the analysis was an array of vectors from which the total magnitude was computed and normalized by the region of interest's number of pixels. This vector flow value was then computed for each pair of consecutive images, generating the optical flow signal used to quantify the microtissue motion over time (pre-and postmeasurement) .
Image analysis of microtissue size. Microtissue area was quantified using MetaXpress software (MetaXpress 5.3 Custom Module Editor, Molecular Devices Corporation, Sunnyvale, California). Transmitted light images were segmented to identify the microtissue and the area of the segmented object measured in mm 2 .
Measurement of cellular ATP content. Cellular ATP concentrations were assessed using the CellTiter-Glo Luminescent Cell Viability Assay as per the manufacturer's instructions (Promega); 40 ll microtissue maintenance media was removed prior to the addition of the CellTiter-Glo reagent. This assay is a luminescence method based on the luciferase/luciferin reaction which determines the number of viable cells present in a well, based on intracellular ATP levels (Lin and Will, 2011) . Data from the same treatment on 4 occasions were averaged to represent the mean ATP measurement.
Data analysis. Data produced were analyzed using Genedata Screener 12 (Genedata AG, Basel, Switzerland). In brief, the preread values were subtracted from the compound response (5 min) and all values scaled relative to the median of the negative (0.1% DMSO, [v/v] ) control wells. The median of the negative control wells was set at 0 and the signals from all wells scaled to this value. Calculations were done with all plates separately to balance out trends and to ensure across plate comparability. Concentration-effect curves were plotted using Screener 12 using an algorithm that excludes outliers and determines an optimal fit using a 4 parameter logistics function. The molar concentration of test compound producing 50% inhibition (IC 50 ) or 50% response (EC 50 ), were calculated for each test compound in quadruplicate and geometric means and 95% CI were subsequently calculated. Receiver operator characteristic (ROC) curves were plotted using Graphpad Prism (La Jolla, California). Therapeutic index (TI) was calculating by dividing the obtained IC 50 or EC 50 by each compound Cmax concentration. T-tests to compare the conditions were performed using Graphpad Prism (La Jolla, California).
RESULTS
Basic Structural Characterization of hiPS-CM Microtissues hiPS-CMs, hCMECs and hCFs were combined in 384-well roundbottom ultra-low adhesion plates. Following 14 days in culture, spontaneously beating cardiac microtissues were formed. All experiments were conducted on microtissues between 14 and 28 days old in a blinded manner. The microtissues formed a uniform shape and size with an average area of 46914 lm 2 6 6070 and 48524 lm 2 6 5074 (n ¼ 10 6 SD) at days 14 and 28,
respectively. This lack of significant difference indicates the stability of the microtissues throughout the experimental period. In order to confirm the presence and integrity of each cell type (cardiomyocytes, endothelial cells, and fibroblasts) immunofluorescence and gene expression analysis was performed with the primary aim to compare the microtissue to human ventricular tissue. Gene expression data was compared with that from one healthy human ventricular sample, which may not fully represent the typical population. Alpha actinin (ACTN2) was used as a specific cardiomyocyte marker ( Figure 1A ), CD31 (PECAM) to mark endothelial cells ( Figure 1B ) and collagen I (COL1A1) or DDR to confirm the presence of fibroblasts ( Figure 1C ). The presence of each cell type within the microtissue was confirmed at both the protein and gene expression level ( Figure 1E ). Microtissues consisted of a heterogeneous population reflected by the close proximity of the endothelial cells and fibroblasts, both to themselves, and to cardiomyocytes ( Figure 1D ). This combined data, of uniform microtissue size and the presence of each key cell marker indicate that this model system is appropriate for cardiotoxicity investigations.
Measuring Contraction in hiPS-CM Microtissues
To determine whether hiPS-CM microtissues were a suitable model to assess the risk of drug-induced effects on cardiac contraction, we used the IonOptix system to directly measure and quantify the contraction and relaxation kinetics of these microtissues. This system measures movement of microtissues in real time, with a continuous flow of cell culture media, during spontaneously beating or following field stimulation at 1, 2, and 3 Hz. (ie, equivalent to 60, 120, and 180 beats/min) ( Figure 2A ). Under these conditions, microtissues had a spontaneous beat rate of 62 6 24 beats/min (mean 6 SD, n ¼ 10). In addition, microtissues were able to maintain synchronized, typical contraction transients following field stimulation (5-7 V for 300 ms) at 1, 2, and 3 Hz, resulting in a mean beat rates of 62 6 3.4, 119 6 0.5 and 176 6 6.9 beats/min, respectively (n ! 3 6 SD) ( Figure 2B) . Analysis of the amplitude of the contraction transients identified a negative frequency-response relationship: as the frequency increased, the amplitude of the contraction transients decreased (n ! 3) ( Figure 2C ).
Having demonstrated that it is possible to measure contraction transients in these microtissues, prior to assessing pharmacology responses, we wanted to ensure the spontaneous beat rate was stable over the period of the experimental protocol (14-28 days). Spontaneous contraction transients were quantified following both 14 and 28 days in culture, resulting in beat rates of 62 6 24 and 61 6 17 beats/min (mean 6 SD, n ¼ 10), respectively, indicating no difference in beat rate over the period of the experimental protocol. Additionally no changes in ATP content was reported throughout the time course (Supplementary Figure S1) . To ensure that these microtissues were able to detect changes in cardiac contraction, the L-type calcium channel blocker, verapamil (a negative inotrope), and the b1-adrenoceptor agonist, dobutamine (a positive inotrope), were assessed on 3 independent occasions in field-stimulated (1 Hz) microtissues. Dobutamine increased the peak amplitude in a concentration dependant manner with an EC50 value of 1.9mM (95% CI ¼ 0.85; 4.3) ( Figure 2E ). Verapamil decreased peak amplitude in a concentration dependant manner with an IC50 value of 5.16 mM (95% CI ¼ 2.02; 13.1) ( Figure 2F ). These data suggest hiPS-CM microtissues are a suitable model system to detect drug-induced changes in cardiomyocyte contractility and provide improved risk assessment compared with hiPS-CM monolayer approaches.
Development of High-Throughput Measurements of Contraction in Microtissues
Via IonOptix these cardiac microtissues could be used to detect changes in cardiac contraction in a low throughput manner.
However a novel higher throughput approach was required to allow application of these microtissues to support the risk assessment of cardiac contraction during drug discovery, allowing the full potential of this model to be utilized. We have combined live cell, fast, time-lapse imaging with motion analysis to allow generation of contraction transients. This approach allows the quantification of the number of contraction transients over time. These contraction measurements were followed by an assessment of cell viability (ATP depletion). TnnI3, PECAM and DDR mRNA expression in the cardiac microtissues relative to adult heart tissue (n ¼ 3, 6SD) determined using qRT-PCR. Scale bar represents 50 lm.
FIG. 2. Measurement of contraction in microtissues.
A, Representative recording of microtissue contractions following spontaneous beating (SB) and field stimulation at 1, 2, and 3 Hz following 14 days in culture. The number of contraction transients over a period of time were quantified (B) (n > 3, mean 6 SD). C, Summary of the frequency-response relationship for contraction (n > 3, mean 6 SD). D, Assessment of the stability of the contraction transients over the period of the experimental protocol (14-28 days) in SB microtissues (n ¼ 10, mean 6 SD). Dobutamine (E) and verapamil (F) concentration-effect curves in microtissues (n ¼ 3, mean 6 SD).
Contractile motion was evaluated prior to and following compound or vehicle addition in cardiac microtissues. Images were acquired at a 10x magnification. At this magnification, the field of view covered the entire bottom of the well ( Figure 3B ). Following image acquisition, images were subjected to a bespoke optical flow analysis ( Figure 3A) . First, the object of interest was identified within the first frame ( Figure 3C ). Following this, an automated binary segmentation was preformed to identify the region of interest. This area was set to be larger than the object to account for any movement of the object within the well ( Figure 3D ). This region of interest was used for the remaining quantification ( Figure 3E ). Using this region of interest, a multiscaled optical flow was computed, generating a vector for each individual pixel. The magnitude of the vector was computed and used as a local motion quantification (Figs. 3F and G) . This vector flow can be plotted to generate a contraction and relaxation trace ( Figure 4A ). Although the contraction and relaxation occurs in opposite directions, the average vector flow is a positive value, thereby resulting in a 2-phase peak profile. The first peak represents contraction ( Figure 3B ) and the second peak represents relaxation ( Figure 3D ). Using these traces we are able to quantify both the number of contractions over a period of time (peak count) and the average amplitude of the contraction peak.
Prior to pharmacological validation of the approach, the variability of contractions was assessed prior to vehicle exposure (0.1% DMSO [v/v] ) (termed pre-measurement), and 5 min following vehicle (termed post-measurement) ( Figure 5A ). Beat rate was found to be 77 6 16.6 and 83 6 16.5 beats/min (mean 6 SD, n ¼ 263), during the pre-and post-measurements, respectively, indicating no difference in beat rate over the period of the experiment (5 min) and additionally that vehicle control (0.1% DMSO [v/v] ) had no impact on the contraction transients. This basal beat rate was not statistically different from data generated using the IonOptix.
Time Lapse Imaging Can Detect Changes in Cardiac Contraction
The potential of this approach to detect a pharmacologically diverse panel of 29 inotropic compounds (clinical or AZ internal drug candidates) with in vivo changes in cardiac contractility (20 negative and 9 positive inotropes) were assessed in duplicate, on 4 independent occasions. Contraction transient traces of each microtissue were generated before addition of compound or vehicle control and 5 min following vehicle control (0.1% DMSO [v/v]) ( Figure 5B ) or compound addition. A visible reduction in the number of contraction transients and transient amplitude was observed following negative inotropes, eg, 1 lM verapamil (L-type calcium channel blocker) ( Figure 5C ) and 100 lM quinidine (class Ia antiarrhythmic, multi ion channel inhibitor) ( Figure 5D ). Whereas, a visible increase in the number of contraction transients and transient amplitude was observed following the positive inotropes, 10 lM dobutamine (b1-adrenoceptor agonist) ( Figure 5E ) and 100 lM milrinone (PDE3 inhibitor) ( Figure 5F ). Traces were further quantified allowing determination of peak count, and subsequent concentration-effect curves and IC 50 (Figs. 6C and D) . In addition to peak count, it is evident from the traces that the amplitude of the peaks is also modulated following compound exposure. To assess the value of quantifying peak amplitude in addition to peak count for the detection of cardiac contractility, a subset of 4 compounds were analyzed. The negative inotropes, verapamil, and quinidine, reduced peak amplitude to varying degrees (Figs. 6E and F) . Whereas, the positive inotropes, dobutamine, and milrinone, increased peak amplitude to varying degrees (Figs. 6G and H) . However, overall the responses observed using peak amplitude as a parameter where similar to those obtained using peak count. Consequently, peak count was used to determine the utility of this approach.
This approach was capable of determining an IC 50 or EC 50 value for all inotropic compounds tested, except AZ3 (Supplementary Table S2 ). None of the tested compounds caused ATP depletion, indicating that all changes seen in contraction transients were not a result of reduced cell viability or cell death, but a consequence of changing the function of the microtissue directly (Supplementary Table S2 ). Additionally, as well as being able to detect both negative and positive inotropes, the direction of these responses was also correct (ie, positive inotropes increased peak count, whereas negative inotropes, decreased peak count).
To ensure that this approach would offer both sensitivity and specificity for the detection of changes in cardiac contraction, 13 clinical and AZ internal drug candidates without an inotroptic risk in preclinical and/or clinical cardiovascular studies were also included with the overall test set (Supplementary Table S3 ). The peak count IC 50 /EC 50 values for each compound were used to plot a ROC curve (Figure 7) . ROC curves are an exhaustive approach to examine paired true-positive (sensitivity) and false-positive rates (1-specificity) for all possible thresholds (Lasko et al., 2005) allowing the outcome of compound effects to be compared with the known effects in vivo.
Use of ROC curves allows appropriate cut-off levels to be selected to judge if a compound is active or inactive in the assay. We found that an IC 50 or EC 50 value of 50 lM or below gave optimal sensitivity and specificity. Using this threshold the sensitivity (ability to detect true positive compounds) of this approach is 80%, whereas the specificity (ability to detect true negative compounds) of this approach is 91%.
Translation of Findings between Different in Vitro Approaches
As various models and approaches are available to assess cardiac contractility in vitro, we investigated whether the pharmacological responses we observed in the cardiac microtissue following the inotropic compounds had similar potency values.
A good correlation was observed between data obtained in canine cardiomyocytes measuring sacromere shortening (r2: 0.7) ( Figure 8A ) (Harmer et al., 2012) and monolayer hiPS-CMs measuring calcium flux (r2: 0.8) ( Figure 8B ) . Additionally, this novel approach using cardiac microtissues overcomes some of the short comings of the monolayer hiPSCMs approaches. For example, the correct direction of inotropy is reported for both positive and negative inotropes in the cardiac microtissue (Figs. 5 and 6) , and the detection of inotropic compounds that inhibit cardiac contractile machinery without modulating calcium flux. For example, the myosin II inhibitor, blebbistatin, reduced peak count, resulting in an IC 50 value of 33.6 lM (CI ¼ 14.07; 80.2) as would be expected in vivo ( Figure 8C ).
As this approach offers advantages over existing in vitro methods to detect cardiac contractility, we questioned whether this approach can detect the in vivo inotropy at relevant therapeutic concentrations. Peak count geometric mean IC 50 /EC 50 (n ¼ 4) were normalized to the therapeutically relevant total maximum plasma concentrations (total C max ) of each inotropic compound and expressed as a ratio, TI. The inotroptic effects of compounds could be divided into 4 categories: (1) peak count was modulated at a concentration of within 30 times the C max , (2) peak count was modulated at a concentration of within 100 times the C max , (3) the inotroptic effect of the compound occurred at concentrations of above 100 times the C max concentration, and (4) the inotroptic effect was not detected in this approach.
In total 23 of the 29 inotropes were detected within a TI of 30-fold and 4 more if a TI of 100 was applied ( Figure 8D ). The remaining 4 compounds not predicted at therapeutically relevant concentrations of <100 times C max were, digoxin, epinephrine, haloperidol, and glibenclamide. Therefore the greater the safety margin between any in vitro inotroptic effects and the therapeutic exposure, the less likely adverse in vitro results will translate to in vivo findings.
DICUSSION
Current approaches to detect drug-induced changes in cardiac contractility in vitro have various shortcomings that limit their use and impact to support the identification, mitigation and elimination of risk in drug discovery. Some models lack the throughput to influence chemical design, eg, "heart on a chip" technology (Grosberg et al., 2011 (Grosberg et al., , 2012 . Some models use isolated cardiomyocytes or organs from preclinical species, having an impact on animal use. For example, the isolated whole heart model and isolated ventricular cardiomyocytes (Guo et al., 2009; Harmer et al., 2012) . Although other models are unable to fully recapitulate the in vivo risk assessment. For example, monolayer hiPS-CMs are unable to discriminate between positive and negative inotropic agents Scott et al., 2014) . Consequently, improved models and assays are required to support the in vitro risk assessment of cardiac contractility during drug discovery.
By assessment of cardiac contraction in a 3D cardiac microtissue, composed of hiPS-CMs, cardiac endothelial cells and cardiac fibroblasts, we have demonstrated the utility of this approach as a suitable model system for the assessment of changes in cardiac contraction. Our data overcome the limitations associated with other in vitro models used to assess cardiac contractility in vitro. For example: the approach described is able to generate hundreds of data points a day (ie, data from approximately 1000 individual microtissues), therefore meeting the throughput required to influence chemical design during drug discovery and development; does not use cells from preclinical species, reducing the use of animals during drug discovery; uses hiPS-CMs, removing the ethical concerns associated with hESC-CMs (Hwang et al., 2015) ; and is not only able to detect the occurrence of changes in cardiac contractility, but is able to discriminate between negative and positive inotropic compounds, thus enhancing the risk assessment of cardiac contractility. Specifically, the b1-adrenoceptor agonist, dobutamine, was able to produce an increase in peak count in the cardiac microtissue, however in monolayer hiPS-CMs a decrease in peak count was observed . This discrimination in inotropy allows the risks of changes in contractility to be contextualized based upon the intended disease and patient population. For example, a positive inotrope is generally not concerning if given to a healthy volunteer; however, in patients with coronary artery disease and or cardiac ischemia, there is an association with increased cardiovascular risk (O'Connor et al., 1999; Tamargo et al., 2009) . Although patients with chronic renal failure, often develop cardiac diastolic dysfunction, and hence a negative inotrope may have a greater effect (Kennedy et al., 2003) . These differential risk factors illustrate the importance of understanding the direction of inotropy when forming an integrated risk assessment.
Microtissues display typical contraction transients comparable to those obtained in adult ventricular cardiomyocytes FIG. 6 . Concentration effect curves. Typical non-cumulative concentration-effect curves generated using peak count and peak amplitude in cardiac microtissues following verapamil (A, E), quinidine (B, F), dobutamine (C, G), and milrione (D, H) (n ¼ 4, mean 6 SD). (Abi-Gerges et al., 2013) and similar pharmacology to reference inotropes, when compared with lower throughput approaches from preclinical species. For example, the positive inotrope, dobutamine in cardiac microtissues results in a peak count EC 50 of 1.87 lM, which compares well with the reported EC 50 value in isolated guinea pig and cat papillary muscle strips; 2 and 0.1 lM, respectively (Brown and Erdmann, 1985; Tuttle and Mills, 1975) . The negative inotrope, verapamil, produced an IC 50 value of 0.17 lM in the cardiac microtissue, again this compared well to data from preclinical species. Specifically, the reported IC 50 value in guinea pig ventricular myocytes is 0.6 lM (Matsuoka et al., 1991) and 0.8 lM in isolated human papillary muscle stripes (Schwinger et al., 1990) . Furthermore, this approach assesses movement of the microtissue directly, rather than measuring a surrogate of the contraction eg, calcium transients. This allows compounds that modulate contractility downstream of the calcium transient to be detected, eg, blebbistatin, allowing the effects on the whole contraction-excitation coupling process to be detected. Consequently, these data illustrate the utility of this approach to detect changes in cardiac contractility at therapeutically relevant concentrations and overcomes the limitations associated with monolayer hiPS-CMs. This is the first study reporting the use of a large, diverse panel of inotropes in combination with advanced cardiac in vitro models, eg, cardiac microtissues. Studies to date have profiled a small number of compounds, typically 2-3, without the inclusion of compounds that do not modulate the response of interest (Hayakawa et al., 2014; Kijlstra et al., 2015) . Our data suggest that measurement of beat rate in cardiac microtissues is able to predict the in vivo outcome (change in dP/dt max or LVEF) with an overall sensitivity of 80% and specificity of 91%. Using the published framework to assess the translation of in vitro data to findings in in vivo models and humans, this approach would be categorized as good to excellent (Genschow et al., 2002; Spielmann et al., 2006) . This compares very favorably with the predictive value of sacomere shortening in canine ventricular cardiomyocytes and calcium transients in hiPS-CMs, which have a sensitivity of 75 and 87% and a specificity of 81 and 70%, respectively, in hiPS-CMs and canine ventricular cardiomyocytes (Harmer et al., 2012; Pointon et al., 2015) . This highlights that not only is this approach able to predict the inotroptic direction of response, it also offers improved specificity without a significant compromise on sensitivity. Despite that this approach does not achieve 100% sensitivity and specificity, this is tolerated when data are combined with that from additional sources allowing an integrated risk assessment and throughput permitting positioning early within drug discovery allowing multiple compounds to be rank ordered. Overall the similarity between different in vitro approaches illustrate that similar data can be obtained in cardiac microtissues to that obtained in electrically-paced adult primary cardiomyocytes and hiPS-CMs.
This novel imaging approach could potentially be used to assess beat rate in hiPS-CM only cultures; however, our previous data suggests that a change in technology platform will not aid the prediction of inotropic effect Scott et al., 2014) . These improvements over existing hiPS-CM contractility assays, could result for a range of possible reasons. It can be hypothesized that the presence of the additional cell types, (cardiac endothelial cells and fibroblasts) could be acting on the cardiomyocytes directly (eg, altered calcium handling or transverse-tubule formation) or indirectly via altered signaling pathways modulating their function, perhaps improving the maturity of the hiPS-CMs (Brutsaert et al., 2003; Camelliti et al., 2005; Souders et al., 2009) . Alternatively, the cardiac microtissues have a higher basal beat rate compared with monolayer hiPS-CMs; this may increase the sensitivity and physiological relevance of the assay. For example, monolayer hiPS-CMs have a reported beat rate of 23 6 5 (mean 6 SD) beats/min ; whereas the cardiac microtissues have a basal beat rate of 62 6 24 (mean 6 SD) beats/min. Data from canine ventricular cardiomyocytes reported increased sensitivity to positive inotropes when the cycle length was reduced from 2000 to 333.33 ms, illustrating that the faster the cells were electrically paced the more potent the pharmacological responses were (Butler et al., 2015) . Additionally, it is widely reported that inhibition of certain ion channel types is rate-dependant, eg, sodium channel blockers typically display marked positive rate dependence (Funck-Brentano, 1993) . Consequently, the increased basal beat rate in cardiac microtissues maybe a contributing factor to the increased prediction of inotropy. In addition, unlike monolayer in vitro preparations, the cardiac microtissues are not attached to a solid surface; therefore, the stiffness of the culture surface is not impacting the force and or movement generated by the cells (Kijlstra et al., 2015; Lo et al., 2000) . The lack of surface resistance may contribute to the increased predictive value of this model system. Finally, altered shape of cardiomyocytes using artificial matrix supports has been linked to changes in cardiac contractility (Ribeiro et al., 2015) , again suggesting that the 3D configuration itself maybe contributing to the effects observed. Further work is required to indentify the exact mechanisms responsible. Conversely, the presence of the noncardiomyocytes could have been hypothesized to hinder the ability of these microtissues to detect changes in cardiac contractility, as these cells move passively with lower motion speed than contracting hiPS-CMs (Hayakawa et al., 2014) . Therefore, perhaps masking the sensitivity of the microtissue to modulation of cardiac contraction. However, this was not found to be true, supported by the correlation to the pharmacological effects in both hiPS-CMs and canine ventricular cardiomyocytes. In order to improve the predictivity further, it is likely that the interaction and influence of other organs would be required to be incorporated. For example many cardiovascular effects are known to be driven via the autonomic nervous system or via the effect of metabolites following drug metabolism in the liver (Pohjola-Sintonen et al., 1993; Yamakawa et al., 2015) . The major limitation that has restricted the utility of imaging techniques to measure cardiac contraction in recent years has been achieving a frame rate that is able to detect changes that occur within milliseconds, in a plate based format. This approach has been able to be overcome this problem through the development of a bespoke workflow designed specifically for this purpose. Other technology platforms that allow an adequate frame rate suffer from the inability to be combined with automated liquid handling or are limited to assessing contraction on individual coverslips rather than in 384 multiwell plates (Hayakawa et al., 2014; Kijlstra et al., 2015) . These limitations restrict the utility during drug discovery, significantly reducing the number of data points able that can be generated per day, limiting the ability of these approaches to influence chemical design through structure-activity relationships. The similarity of data obtained using edge detection (IonOptix), confirms that this approach is able to detect changes in cardiac contraction with a sufficient frame rate.
Analysis of cardiac contractility typically allows quantification of various parameters derived from the contraction traces obtained (Harmer et al., 2012; Sirenko et al., 2013) . However, previous analysis revealed that no mechanistic insight was gained through looking at additional parameters above peak count for cardiac contractility . This is not surprising as the width, rise, or decay time change the numbers of peaks present over a set period of time. For example, as the peak width increases, the time it takes for one beat increases, as one beat has to finish before the next commences. Therefore less beats are possible in a set period of time. The same phenomena are true for changes in rise and decay time. Consequently, these parameters were not assessed in this study. However, it is possible that peak amplitude is independent of peak count. Initial analysis of both peak count and peak amplitude in this data set revealed that peak amplitude did not add any additional value to peak count alone. Additionally the peak amplitude depends on the heterogeneity of each microtissue as the noncardiomyocytes do not contract, but move passively. As these cardiac microtissues are composed of 3 cell types, 2 of which are non-cardiomyocytes, it is possible that the heterogeneity will vary between microtissues, impacting the stability of peak FIG. 8 . Correlation of the potency values obtained following measurement of cardiac contraction transients in cardiac microtissues and sarcomere shortening in canine ventricular myocytes (A) and calcium transients in hiPS-CMs (B); the dotted line shows the line of unity. Non-cumulative concentration-effect curves generated using peak count in cardiac microtissues following blebbistatin (C) (n ¼ 3, mean 6 SD). D, Potency values (n ¼ 3) obtained in cardiac microtissues were normalized to the total Cmax of each compound and expressed as a ratio (TI). A value of one or below indicates the IC50/EC50 for an assay was either at or below Cmax concentrations, whereas a value >1 indicates the IC 50 /EC 50 for an assay was above C max concentrations. The plot shows the TI which compounds were detected at. The slash line represents hundred times C max .
amplitude as a parameter. Last, incorporation of multiple measurements into an early decision-making process can complicate interpretation (Lu et al., 2015) . Even though additional parameters derived from the contraction trace, other than peak count, do not provide mechanistic insight, the lack of changes in ATP (cell viability) reveal that at the physiology level these compounds are causing a direct effect on cardiac contraction without any change in cell death or energy utilization in the time-frame and concentration range tested.
In conclusion, our data show that cardiac microtissues provide a suitable model for the detection of drug-induced changes in cardiac contraction, overcoming the limitations of monolayer hiPS-CMs. This format used is applicable to drug discovery, allowing improved risk assessment and a reduction in the use of animals for ex vivo applications. If used in this manner, this approach can contribute towards an improved balance between efficacy and safety of novel compounds.
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